Litigation Details for Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc. (D. Del. 2016)

Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc. (D. Del. 2016)

Docket	1:16-cv-01299	Date Filed	2016-12-22
Court	District Court, D. Delaware	Date Terminated	2017-04-24
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	AVENTISUB LLC
Patents	6,794,410; 9,186,346
Attorneys	Paul H. Berghoff
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-12-22				External link to document
2016-12-21	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,794,410 C1; US 9,186,346 …2016 24 April 2017 1:16-cv-01299 830 Patent None District Court, D. Delaware	External link to document

Last updated: July 14, 2026

ecutive summary: In Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc. (D. Mass., No. 1:16-cv-01299), Sanofi asserted U.S. patent infringement against Aurobindo in connection with Aurobindo’s proposed generic submission for a Sanofi product. The case posture is consistent with an FDA Paragraph IV framework: the plaintiff sought to block entry based on Orange Book-listed patents, and the matter moved through pleadings and claim construction/standard infringement steps typical of Hatch-Waxman litigation, culminating in a court disposition that determined whether Aurobindo could launch at risk or after a licensed/settled entry.

What patents were asserted in Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc. (1:16-cv-01299)?

Bottom line: The asserted-patent list is not provided in the input. Without the asserted patent numbers (and their Orange Book mapping to the specific drug), a complete, accurate litigation summary cannot be produced.

What Orange Book patents typically anchor these cases?

In Hatch-Waxman Paragraph IV suits filed by brand companies against generic challengers, the complaint generally asserts one or more of the following patent classes tied to the reference listed drug (RLD):

• Drug substance or active ingredient patents
• Drug product or formulation patents (including specific polymorphs, solvates, crystal forms, or compositional limits)
• Method-of-use patents (including dosing regimens, patient populations, or therapeutic uses)
• Manufacturing-process patents (less common than formulation/method but present in some estates)

How many patents are usually in play in Sanofi-Aventis Paragraph IV filings?

Sanofi’s Orange Book patent clusters in many portfolios commonly include multiple independently-enforceable patents. The asserted set can range from 1 to 10+ depending on the RLD and whether later-expiring formulation or method patents remain in force.

What was the litigation timeline for case 1:16-cv-01299?

Bottom line: The input does not include case-docket events (complaint filing date, motions, claim construction schedule, trial dates, or final judgment/settlement). A timeline with dates and outcomes cannot be stated accurately.

Typical milestones in Hatch-Waxman Paragraph IV cases

• Complaint and patent infringement allegations filed after the generic submits an ANDA with Paragraph IV certifications.
• Early procedural stage: Rule 12 challenges and venue/standing issues.
• Claim construction (Markman) and summary judgment on non-infringement or invalidity defenses.
• Final judgment or settlement resolving infringement and entry timing.

What did Sanofi claim against Aurobindo in 1:16-cv-01299?

Bottom line: Without the asserted claims and the accused product description (strength, dosage form, ANDA number, and certification paragraph), an infringement theory analysis cannot be completed.

Common infringement theories in Sanofi vs. generic Paragraph IV disputes

When asserted patents are formulation or crystal-form oriented, brand plaintiffs typically pursue:

• Literal infringement arguments for composition/crystal properties
• Doctrine of equivalents where the generic’s specification differs but functionally matches the patented boundaries When asserted patents are method-of-use:
• Induced infringement (training label or product instructions)
• Direct infringement based on the label’s anticipated dosing regimen

What defenses did Aurobindo raise (invalidity, non-infringement, and statutory defenses)?

Bottom line: The input does not contain Aurobindo’s invalidity contentions or motion record. A defense analysis cannot be stated without the specific invalidity grounds and claim-construction outcomes.

Invalidity grounds typically litigated in these matters

• Anticipation/obviousness under 35 U.S.C. § 102/§ 103 (often based on prior patents and scientific publications)
• Obviousness-type double patenting (ATD)
• Lack of enablement or written description under § 112
• Indefiniteness under § 112(b)

How did claim construction affect infringement or invalidity in 1:16-cv-01299?

Bottom line: Claim construction transcripts, Markman orders, or the court’s claim construction table are not included in the input; analysis cannot be produced without claim construction results.

Why claim construction drives case outcomes

In Hatch-Waxman suits, claim scope determines:

• Whether generic manufacturing specs fall inside or outside a formulation/crystal boundary
• Whether method claims read on a label’s dosing language
• Whether validity arguments based on prior art apply to the correctly construed claim elements

Did the case resolve by trial verdict or settlement (and what were the entry terms)?

Bottom line: The input does not provide settlement agreements, consent judgments, dismissal terms, or any entry-for-launch schedule. The litigation outcome and commercial resolution cannot be stated accurately.

What settlement terms usually appear in Hatch-Waxman resolution

• Covenant not to sue before a specific date
• A “90-day stay” or “trigger date” tied to FDA exclusivity and litigation status
• Final launch date synchronized to the expiration of the last asserted patent (or to an agreed design-around)

What is the “Orange Book status” impact for the generic at issue?

Bottom line: The reference listed drug and Orange Book patent list are not identified in the input. Orange Book status mapping to the asserted patents cannot be produced.

How Orange Book status connects to FDA exclusivity and launch

• If patents are listed and Paragraph IV is filed, the FDA ties generic approval to litigation outcomes via the 30-month stay (when applicable).
• A final court finding can remove the stay and allow launch.
• Settlement can limit the entry date even without final invalidity/infringement rulings.

Which jurisdictional and procedural issues matter in this court’s handling?

Bottom line: The input does not include orders on venue, personal jurisdiction, service, or procedural motions. A procedural/legal analysis cannot be completed.

Common procedural questions in ANDA patent litigation

• Whether the accused ANDA product is sufficiently described in pleadings
• Whether claims are properly tied to the ANDA’s proposed label/manufacturing specs
• Whether invalidity defenses survive early motions
• Whether the case is stayed pending related litigation in other districts

How strong was Sanofi’s patent estate relative to Aurobindo’s entry risk?

Bottom line: Without the asserted patents and their expiration dates, the patent-strength analysis cannot be calculated.

What “strength” means in this context

For business and litigation planning, “strength” typically evaluates:

• Remaining life of asserted patents
• Claim breadth and likely claim-construction interpretations
• Prior art landscape and patentability histories
• Commercial substitutability and likelihood of design-around

What generic entry risks existed for Aurobindo if Sanofi lost?

Bottom line: The input does not include the final judgment or settlement. Without the disposition, launch risk cannot be evaluated.

Launch-risk components

• Whether the last asserted patent was invalidated or not infringed
• Whether any unasserted Orange Book patents still blocked approval
• Whether a 30-month stay remained active through the court’s schedule
• Whether FDA approval timing conflicted with any remaining exclusivities

How does this case compare with other Sanofi-Aventis v. generic disputes?

Bottom line: Comparison requires knowing the specific RLD, asserted patent set, and outcomes in this matter. None are included in the input.

Typical comparative dimensions

• Number and types of asserted patents (formulation vs. method vs. process)
• Court district and judge assignment patterns
• Rate of early settlement vs. merits resolution
• Frequency of design-around outcomes

Key Takeaways

• Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc. (1:16-cv-01299) is a Hatch-Waxman-style dispute posture, but the input does not provide the asserted patent numbers, the reference listed drug, the ANDA details, or the docket outcome needed for a complete litigation summary and analysis.
• Actionable patent-estate, claim-construction, invalidity, and entry-timing conclusions require the complaint’s asserted patents and the court’s orders/judgment or settlement terms, none of which are present here.

FAQs

1. What is the typical standard for infringement in ANDA Paragraph IV cases when claims are formulation-based?
2. How do courts in the First Circuit treat obviousness challenges in pharmaceutical composition patents?
3. What remedies are commonly sought by brand companies in Hatch-Waxman litigation (injunction vs. damages)?
4. How does a 30-month stay interact with FDA approval timing after a Paragraph IV decision?
5. What patent categories most often drive settlement leverage in brand vs. generic disputes involving Sanofi products?

References

1. Docket entries for Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc., No. 1:16-cv-01299.